ArticleThe pharmacogenomics journal2026
A functional ancestry-linked regulatory haplotype influences CYP2D6 expression.
Article in The pharmacogenomics journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PharmVar GeneFocus: CYP1A2-Clinical Impact, Genetic Variation, and Updated Nomenclature.Clinical pharmacology and therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytochrome P450 (CYP) enzymes metabolize 70-80% of therapeutic agents, yet regulatory variants affecting drug metabolism remain poorly characterized across populations. Although numerous studies have examined coding variants in pharmacogenes, comprehensive analysis of regulatory variation across tissues and ancestries is lacking. Expression quantitative trait loci (eQTLs) for 54 CYP genes were analyzed using GTEx data, identifying CYP2D6 as harboring the most extensive regulatory variation, with 249 variants including two high-effect variants in strong linkage disequilibrium. In silico functional analysis predicts that one variant disrupts thousands of transcription factor binding sites in a region of high chromatin accessibility. Both variants exhibit population stratification, occurring at 45% frequency in East Asian populations versus 2.5% in Europeans, and show strong linkage with the reduced-function CYP2D6*10 allele. These results indicate that ancestry-specific regulatory variants should be incorporated into pharmacogenetic testing strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.